These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10826894)

  • 1. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
    Penzak SR; Chuck SK
    Scand J Infect Dis; 2000; 32(2):111-23. PubMed ID: 10826894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlipidemia associated with protease inhibitor therapy.
    Echevarria KL; Hardin TC; Smith JA
    Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
    Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
    AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
    Stein JH; Klein MA; Bellehumeur JL; McBride PE; Wiebe DA; Otvos JD; Sosman JM
    Circulation; 2001 Jul; 104(3):257-62. PubMed ID: 11457741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperlipidemia in HIV-positive patients receiving antiretrovirals.
    Segarra-Newnham M
    Ann Pharmacother; 2002 Apr; 36(4):592-5. PubMed ID: 11918504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating hyperlipidaemia associated with antiretroviral therapy.
    Mauss S; Stechel J; Willers R; Schmutz G; Berger F; Richter WO
    AIDS; 2003 Jan; 17(2):189-94. PubMed ID: 12545078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid abnormalities associated with protease inhibitors.
    Melroe NH; Kopaczewski J; Henry K; Huebsch J
    J Assoc Nurses AIDS Care; 1999; 10(2):22-30. PubMed ID: 10065407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.
    Chuck SK; Penzak SR
    Expert Opin Drug Saf; 2002 May; 1(1):5-17. PubMed ID: 12904155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intervention for hyperlipidemia associated with protease inhibitors.
    Melroe NH; Kopaczewski J; Henry K; Huebsch J
    J Assoc Nurses AIDS Care; 1999; 10(4):55-69. PubMed ID: 10394560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
    Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
    HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood lipid abnormalities during treatment with protease inhibitors].
    Vergès B; Petit JM
    Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.